These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

605 related items for PubMed ID: 15930315

  • 1. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, Myers D, Nakamura A, Waltham MC, Gillespie MT, Thompson EW.
    Cancer Res; 2005 Jun 01; 65(11):4929-38. PubMed ID: 15930315
    [Abstract] [Full Text] [Related]

  • 2. HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors.
    van der Kraan AG, Chai RC, Singh PP, Lang BJ, Xu J, Gillespie MT, Price JT, Quinn JM.
    Biochem J; 2013 Apr 15; 451(2):235-44. PubMed ID: 23379601
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
    Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, Workman P.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):7023-32. PubMed ID: 16203796
    [Abstract] [Full Text] [Related]

  • 4. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
    Fisher JL, Thomas-Mudge RJ, Elliott J, Hards DK, Sims NA, Slavin J, Martin TJ, Gillespie MT.
    Cancer Res; 2006 Apr 01; 66(7):3620-8. PubMed ID: 16585187
    [Abstract] [Full Text] [Related]

  • 5. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
    Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, Gius D.
    Cancer Res; 2003 Dec 15; 63(24):8984-95. PubMed ID: 14695217
    [Abstract] [Full Text] [Related]

  • 6. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
    Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, Skinner RA, Swain F, Ramani V, Mohammad KS, Wessner LL, Martinez A, Guise TA, Chirgwin JM, Gaddy D, Suva LJ.
    Cancer Res; 2005 Dec 01; 65(23):11001-9. PubMed ID: 16322249
    [Abstract] [Full Text] [Related]

  • 7. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
    Roforth MM, Tan C.
    Anticancer Drugs; 2008 Aug 01; 19(7):681-8. PubMed ID: 18594209
    [Abstract] [Full Text] [Related]

  • 8. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.
    Yin X, Zhang H, Burrows F, Zhang L, Shores CG.
    Clin Cancer Res; 2005 May 15; 11(10):3889-96. PubMed ID: 15897590
    [Abstract] [Full Text] [Related]

  • 9. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.
    Kurio N, Shimo T, Fukazawa T, Takaoka M, Okui T, Hassan NM, Honami T, Hatakeyama S, Ikeda M, Naomoto Y, Sasaki A.
    Exp Cell Res; 2011 May 01; 317(8):1134-46. PubMed ID: 21338601
    [Abstract] [Full Text] [Related]

  • 10. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
    Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D.
    Cancer Res; 2005 Nov 01; 65(21):10006-15. PubMed ID: 16267026
    [Abstract] [Full Text] [Related]

  • 11. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L.
    Clin Cancer Res; 2003 Oct 15; 9(13):4961-71. PubMed ID: 14581371
    [Abstract] [Full Text] [Related]

  • 12. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
    Kitazawa S, Kitazawa R.
    J Pathol; 2002 Oct 15; 198(2):228-36. PubMed ID: 12237883
    [Abstract] [Full Text] [Related]

  • 13. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
    Kaur G, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, Riccardi E, Thillainathan J, Hollingshead M, Sausville EA, Giavazzi R.
    Clin Cancer Res; 2004 Jul 15; 10(14):4813-21. PubMed ID: 15269157
    [Abstract] [Full Text] [Related]

  • 14. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
    Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T.
    Cancer Res; 1995 Aug 15; 55(16):3551-7. PubMed ID: 7627963
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
    Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N.
    Cancer Res; 2003 May 01; 63(9):2139-44. PubMed ID: 12727831
    [Abstract] [Full Text] [Related]

  • 16. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
    Wilson TJ, Nannuru KC, Futakuchi M, Sadanandam A, Singh RK.
    Cancer Res; 2008 Jul 15; 68(14):5803-11. PubMed ID: 18632634
    [Abstract] [Full Text] [Related]

  • 17. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
    Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ.
    Cancer Res; 2001 Jun 01; 61(11):4432-6. PubMed ID: 11389072
    [Abstract] [Full Text] [Related]

  • 18. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM.
    Clin Cancer Res; 2006 Nov 15; 12(22):6826-35. PubMed ID: 17121904
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells.
    Münster PN, Srethapakdi M, Moasser MM, Rosen N.
    Cancer Res; 2001 Apr 01; 61(7):2945-52. PubMed ID: 11306472
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.